Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.49 |
| ▸ | NPY1R | P25929 | 5/20 | 0.49 |
| ▸ | NPY2R | P49146 | 3/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.48 |
| ▸ | CD40 | P25942 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26428962 | 0.86 | GRIA1 (0.54) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL26428986 | 0.86 | GLP1R (0.46) | — | |
| SCHEMBL26428944 | 0.84 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RGRIA1 | |
| SCHEMBL16525843 | 0.77 | GLP1R (0.56) | — | |
| SCHEMBL45885 | 0.77 | GLP1R (0.56) | — | |
| SCHEMBL27115934 | 0.77 | CHRND (0.57) | GRIA1 | |
| SCHEMBL27143158 | 0.77 | CHRND (0.57) | GRIA1 | |
| SCHEMBL12680289 | 0.76 | ALB (0.48) | NPY4RNPY5RNPY1RNPY2RGRIA1 | |
| SCHEMBL27117717 | 0.76 | CHRND (0.53) | NPY4RNPY5RNPY1RNPY2RGRIA1 | |
| SCHEMBL14479373 | 0.75 | CHRND (0.52) | CD40GRIA1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | NATIONAL SCIENCE FOUNDATION | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | MFAP1, DIAPH1, SEPTIN7 | NPY4R 1036/4885NPY5R 447/4885NPY1R 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.